TrialBMC cancer2016

Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma.

Marjolijn van Keep et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.